Send me real-time posts from this site at my email

Protagonist Therapeutics (PTGX) Received its Third Buy in a Row

After Piper Sandler and H.C. Wainwright gave Protagonist Therapeutics (NASDAQ: PTGX) a Buy rating last month, the company received another Buy, this time from JMP Securities. Analyst Gobind Singh maintained a Buy rating on Protagonist Therapeutics today and set a price target of $47.00. The company's shares closed last Monday at $35.94.

According to, Singh is ranked 0 out of 5 stars with an average return of -33.3% and a 6.3% success rate. Singh covers the Healthcare sector, focusing on stocks such as Kaleido Biosciences, Seres Therapeutics, and Evelo Biosciences.

Currently, the analyst consensus on Protagonist Therapeutics is a Strong Buy with an average price target of $52.33, a 53.6% upside from current levels. In a report issued on October 4, Leerink Partners also maintained a Buy rating on the stock with a $35.00 price target.

See today’s analyst top recommended stocks >>

Protagonist Therapeutics' market cap is currently $867.3M and has a P/E ratio of -9.50. The company has a Price to Book ratio of 2.43.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Read More on PTGX:

The post Protagonist Therapeutics (PTGX) Received its Third Buy in a Row appeared first on TipRanks Financial Blog.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue